×
Can Google be trusted without a break up?

Can Google be trusted without a break up?

On day three of the two-week remedies trial in the Justice Department’s ad tech case against Google, Judge Leonie Brinkema boiled down the argument to one key issue: trust. Brinkema interrupted testimony from a DOJ expert with a hypothetical: should she issue a strict order modifying Google’s behavior, could it resolve the issues at hand if “you had confidence that Google would actually act in complete good faith?”

The question felt particularly pointed, given how the Google trial Brinkema presided over last year unfolded. Over three weeks, the DOJ repeatedly presented examples of Google employees allegedly using chat messages to avoid leaving a paper trail for discovery. Brinkema later said the practice represented “systemic disregard of the evidentiary rules.” While she opted not to sanction Google for its lax approach to preserving evidence, she warned not to take its decision as condoning the behavior.

Soon, Brinkema will decide how hard to crack down on the monopoly that she ruled Google holds in ad tech. That decision may hinge on whether she thinks it will follow the rules this time.

Google’s remedies proposal involves a court order banning specific business practices and requiring it to engage in the ad auction process in ways similar to its rivals. But the DOJ says that leaves it easily capable of monopolizing the market again. The government wants to take power out of Google’s hands altogether by making it spin off ad exchange AdX and open source part of (and possibly even sell) its DFP tool for web publishers.

It’s the second time in just a few months that a judge has faced the question of breaking up Google. In a separate case over Google’s search monopoly, Judge Amit Mehta declined to do so, opting for lower-lift remedies like banning anticompetitive practices and sharing data. The facts that led Mehta to decide against a break up have no bearing on this case, the government argued in its opening statement. Still, Brinkema’s ruling could be an indicator of how widely judges share Mehta’s caution, as more cases against Big Tech companies roll toward a trial.

“The devil is in the details”

The DOJ was still in the midst of its case-in-chief on Friday, but Google’s attorneys were already driving at their core argument: that the government is underselling how difficult and risky its asks are. Google advertising executive Tim Craycroft testified that the DOJ’s proposals were “naive” and “incoherent.” This line of thinking seemed to land with the judge by mid-week. “The devil is in the details,” she said during the testimony of Jonathan Weissman, the DOJ’s expert witness on the technical feasibility of a break up. After he compared changing Google’s ad tech tools to changing tires on a car, Brinkema noted that a change to snow tires could result in a “bumpier” ride for the user.

But during Craycroft’s testimony, Brinkema appeared to entertain an even more extreme option the government hadn’t asked for: shutting down AdX altogether. This was apparently something Google itself considered within the past few years in an analysis it called “Project Monday,” Craycroft said.

“Why is that not a very simple and elegant solution?” Brinkema asked, after Craycroft noted that another Big Tech company could buy AdX and create its own monopoly. Though several ad exchanges exist today, the court found they’ve been denied a level playing field because of tactics like reserving full real-time bidding access to Google’s huge advertiser base through its own tools. Publishers testified in the liability trial that made it nearly impossible to leave, even though AdX was charging a supracompetitive take rate of 20 percent on transactions. Craycroft told the judge that deprecating AdX could be an elegant solution, but that would also get rid of other helpful features in the product.

Brinkema made clear she wants to learn what’s actually possible, as she considers options for leveling the playing field without harming publishers and advertisers who rely on Google products.

Google found a so-called business divestiture of AdX would be feasible within two years, Craycroft said, including offloading IP, moving customer contracts, and providing reference code to guide the buyer through duplicating product functions in its own systems. But he stressed Google couldn’t realistically provide source code guaranteed to work in an unknown buyer’s tech stack, as the DOJ requests. Former Facebook capacity engineer Goranka Bjedov, who helped migrate Instagram and WhatsApp during their acquisitions, testified that the reference source code would be sufficient for a full migration. If Brinkema finds a divestiture is possible, she’ll have to decide if she trusts Google enough not to force one.

Even after helping Google’s attorneys craft their remedies proposals, Craycroft told DOJ attorney Matthew Huppert that he could not commit to lowering AdX’s 20 percent take rate, which the judge had ruled to be above a competitive level, and said a tie between DFP and access to AdX real-time bidding, a sticking point for publishers, was “just how the product was built.”

The answer to Brinkema’s question about trust wasn’t necessarily reassuring for Google. Robin Lee, the Harvard economist she asked, said the problem was how many different ways Google could get around the intentions behind a court order. Lee said there’s an almost unpredictably exhaustive list of methods for tilting the scales in Google’s favor, and it’s got every incentive to take them.

Longtime Google critics were disappointed after Mehta’s ruling didn’t include a breakup. If Brinkema reaches a similar conclusion, The Trade Desk Chief Revenue Officer Jed Dederick testified, “I think there will be a sense that they got away with it.”

Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.


Source link
#Google #trusted #break

confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date

OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

Post Comment